DAFNA Capital Management »

Ascendis Pharma AS shares owned by DAFNA Capital Management

Quarter-by-quarter ownership of Ascendis Pharma AS (ASND) shares owned by DAFNA Capital Management from 13F filings

Historical chart of DAFNA Capital Management investment in Ascendis Pharma AS

Tip: Access up to 7 years of quarterly data

All positions including Ascendis Pharma AS held by DAFNA Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Ascendis Pharma AS by DAFNA Capital Management

Quarter filed Position value Share count Share price at filing
2026-06-30 $13M 49k 266.72

More positions owned by DAFNA Capital Management

Revolution Medicines (RVMD)
Spdr S&p Biotech Etf Etf (XBI)
Compass Pathways Sponsored Ads (CMPS)
Stereotaxis Com New (STXS)
Nektar Therapeutics Com New (NKTR)
Denali Therapeutics (DNLI)
Ideaya Biosciences (IDYA)
AtriCure (ATRC)
Xenon Pharmaceuticals (XENE)
Cytokinetics Com New (CYTK)
Arcus Biosciences Incorporated (RCUS)
Ascendis Pharma A/s Ord Shs (ASND)
Neurocrine Biosciences (NBIX)
Axogen (AXGN)
Insulet Corporation (PODD)

View all positions for DAFNA Capital Management

Top funds holding Ascendis Pharma AS

RA Capital Management
venBio Select Advisor
Westfield Capital Management Company
Jupiter Topco
FMR
Artisan Partners Limited Partnership
Capital Research and Management Company - Division 3
Massachusetts Financial Services
Franklin Resources
Wellington Management Company
T. Rowe Price Associates
American Century Companies
Perceptive Advisors
Principal Financial Group
Polar Capital Holdings

View all funds holding Ascendis Pharma AS